BLLN vs BMY: fair value comparison
BillionToOne, Inc. and Bristol-Myers Squibb Company · Updated 2026-10-19
BLLN's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, BLLN currently ranks higher by quality score.
| BLLN | BMY | |
|---|---|---|
| Verdict | Awaiting full valuation | Overvalued |
| Last price | $98.12 | $59.12 |
| 12-month range | $64.03–$149.97 | $42.60–$68.09 |
| Rank by discount to fair value | — | #72 of 108 Healthcare |
| Rank by quality score | #75 of 301 Healthcare | #76 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Low | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BLLN fair value analysis · BMY fair value analysis